Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

AREG (Amphiregulin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

AREG overexpression	Colorectal Cancer	AREG overexpression	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
AREG overexpression	Squamous Cell Carcinoma of Head and Neck	AREG overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3
AREG overexpression	Colorectal Cancer	AREG overexpression	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
AREG expression	Squamous Cell Carcinoma of Head and Neck	AREG expression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
AREG expression	Colon Cancer	AREG expression	Colon Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
AREG overexpression	Colorectal Cancer	AREG overexpression	Colorectal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
AREG overexpression	Pancreatic Cancer	AREG overexpression	Pancreatic Cancer	cetuximab Resistant: C4 – Case Studies cetuximab Resistant : C4	cetuximab Resistant: C4 – Case Studies cetuximab Resistant : C4
AREG overexpression	Gastric Cancer	AREG overexpression	Gastric Cancer	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D